ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
14.87
-1.08 (-6.77%)
At close: Oct 30, 2026, 4:00 PM EDT
14.85
-0.02 (-0.13%)
After-hours: Oct 30, 2026, 7:30 PM EDT
ArriVent BioPharma Earnings Call Transcripts
Fiscal Year 2026
-
ARR-217 showed a 44.8% ORR and 93.1% DCR at 6 mg/kg in heavily pretreated metastatic CRC, with mostly low-grade toxicity and 2% Grade 3 diarrhea. Phase Ib monotherapy and combination studies continue; phase III initiation is targeted by end-2027.
-
The meeting confirmed a quorum and proceeded virtually, electing three directors for terms ending in 2029 and ratifying PricewaterhouseCoopers LLP as auditor for 2026. No questions were received from stockholders during the Q&A session.